Related Experiment Video
Updated: Aug 16, 2026
09:29
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Oromucosal interferon therapy: relationship between antiviral activity and viral load
H Schellekens1, G Geelen, J F Meritet
1Department of Medical Microbiology, University of Utrecht, The Netherlands.
Summary
Oromucosal interferon-alpha (IFN) effectively protected mice against low-dose encephalomyocarditis virus (EMCV) infection, unlike high-dose challenges. This suggests oromucosal IFN may be a viable alternative for chronic viral infections.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Recombinant murine interferon-alpha (rMuIFN-alpha) is a potential therapeutic agent for viral infections.
- Parenteral administration of IFN-alpha is effective but often poorly tolerated.
- Alternative delivery methods for IFN-alpha are being explored for improved patient compliance and reduced side effects.
Purpose of the Study:
- To evaluate the efficacy of oromucosal (o.m.) interferon-alpha (IFN) therapy compared to intraperitoneal (i.p.) administration in protecting mice against encephalomyocarditis virus (EMCV) challenge.
- To determine the dose-dependency and effectiveness of o.m. IFN therapy in relation to viral load.
- To explore potential differences in the mechanism of action between o.m. and i.p. IFN therapy.
Main Methods:
- Mice were challenged with varying lethal doses (LD50) of EMCV.
- Mice received either i.p. or o.m. administration of 20,000 IU rMuIFN-alpha.
- Survival rates and mean survival times were recorded and compared between treatment groups and controls.
Main Results:
- Intraperitoneal rMuIFN-alpha (20,000 IU) was highly effective against EMCV doses from 44 to 440 LD50, significantly increasing survival rates (p<0.001).
- Oromucosal rMuIFN-alpha (20,000 IU) provided significant protection against a low dose (44 LD50) of EMCV, increasing survival time (p<0.05).
- Oromucosal IFN therapy was ineffective against higher EMCV doses (88-440 LD50), whereas i.p. administration remained effective.
Conclusions:
- Oromucosal IFN therapy demonstrates efficacy primarily at lower viral loads.
- The therapeutic mechanism of oromucosal IFN may differ from that of parenteral administration.
- Oromucosal IFN therapy presents a potential alternative for managing chronic viral infections, offering improved tolerability over parenteral routes.
Related Concept Videos
01:29Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...